Serotonin receptor agonist and risk of paresthesia in migraine patients: A dose-response model-based (network) meta-analysis

Conclusions: This meta-analysis of reported placebo-controlled clinical trials suggests that the SUCRA probabilities for the manifestation of paresthesia are higher with Lasmiditan. The relative risk of paresthesia is higher with the use of Topiramate 200 mg, Lasmiditan 400 mg, and Zolmitriptan 10 mg. In addition, Lasmiditan exhibited a gradual dose-response of relative risk for the manifestation of paresthesia.
Source: Annals of Indian Academy of Neurology - Category: Neurology Authors: Source Type: research